Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Note 9 - Accrued Expenses and Other Long-term Liabilities

12 Months Ended

Dec. 31, 2016

9.	Accrued Expenses and Other Long-Term Liabilities

Other accrued expenses consisted of the following as of

December

31,

2016

and

2015:

	December 31, 2016		December 31, 2015
Accrued royalties	$	711	$	111
Insurance and benefit accruals		40		366
Indemnification liability		875		875
Contingent consideration		260		659
Rent payable		110		127
DOJ settlement		80		250
Accrued professional fees		1,746		775
Taxes payable		526		591
Unclaimed property		565		546
Directors fees and insurance		40		107
All others		1,283		1,554
Total other accrued expenses	$	6,236	$	5,961

Other long-term liabilities consisted of the following as of

December

31,

2016

and

2015:

	December 31, 2016		December 31, 2015
Rent payable	$	-	$	52
Uncertain tax positions		3,594		3,425
DOJ settlement (indemnified by RedPath)		250		2,500
Other		-		201
Total other long-term liabilities	$	3,844	$	6,178